Danaher (DHR) Stock: Analysts Cut Price Targets After Bioprocessing Weakness

TLDR

• Danaher stock is down ~11% this week and 21% year-to-date, trading at $179.01
• Q2 adjusted EPS of $1.94 beat estimates of $1.83; revenue of $6.3B topped the $6.1B forecast
• Bioprocessing segment disappointed, posting only low single-digit growth
• Guggenheim, Stifel, and BofA all cut price targets but kept Buy ratings
• 10 analysts have revised earnings estimates downward for the upcoming period

---

Danaher posted a Q2 earnings beat but the market wasn’t impressed. The stock fell roughly 11% on the week, hitting $179.01, as investors zeroed in on weakness in the bioprocessing segment rather than the headline numbers.

Danaher Corporation, DHR

Adjusted EPS came in at $1.94, clearing the $1.83 consensus estimate. Revenue reached $6.3 billion, ahead of the $6.1 billion forecast. On paper, a solid quarter.

But bioprocessing told a different story. The segment posted low single-digit growth — well below expectations — and Danaher attributed the softness to timing factors tied to specific products for specific customers.

Not everyone is buying that explanation. Questions about market share dynamics have surfaced, and analysts flagged a lack of clarity around the miss.

BofA analyst Michael Ryskin described the quarter as “certainly messier than expected,” driven by the bioprocessing shortfall. He cut his price target from $270 to $230 but kept a Buy rating.

Ryskin also noted that this is “not the first setback or headwind to pop up in recent years” for Danaher, adding that the company now has to rebuild confidence in both the business and its execution.

Analysts Cut Targets Across the Board

Guggenheim trimmed its target from $235 to $200, also keeping a Buy rating. The firm flagged ongoing uncertainty in the bioprocessing segment and said the issue will likely come up across several peer earnings reports this week.

Stifel moved its target from $260 to $220, maintaining Buy. The firm pointed to continued softness expected in Q3 and noted that Q4 growth would need to hit mid-single digits just to round up to the bottom end of the full-year 3% outlook.

Across all three firms, the Buy ratings remained intact. InvestingPro data suggests the stock looks undervalued at current levels despite the sell-off.

What Comes Next

Danaher still projects high single-digit growth potential for its bioprocessing business. But getting there requires Q4 to deliver, and investor confidence is thin right now.

Stifel said the near-term outlook depends heavily on how the broader Tools sector earnings cycle plays out. If confidence in the sector holds, DHR could recover. If it doesn’t, Stifel sees Danaher positioned to underperform.

Ten analysts have now revised their earnings estimates downward for the upcoming period.

Danaher stock is down 21% year-to-date as of July 22, 2026.